Skip to main content
. Author manuscript; available in PMC: 2023 Feb 1.
Published in final edited form as: Clin Pharmacol Ther. 2021 Jun 20;111(2):366–372. doi: 10.1002/cpt.2309

TABLE 1.

ASSIGNMENT OF MT-RNR1 PHENOTYPE BASED ON GENOTYPE

Likely phenotype Genotypes Example genotypes
MT-RNR1 increased risk of aminoglycoside-induced hearing loss Individuals with a MT-RNR1 variant associated with an increased risk of aminoglycoside-induced hearing loss m.1095T>C
m.1494C>T
m.1555A>G
MT-RNR1 normal risk of aminoglycoside-induced hearing loss Individuals with no detectable MT-RNR1 increased risk variant or a MT-RNR1 variant associated with normal risk of aminoglycoside-induced hearing loss m.827A>G
MT-RNR1 uncertain risk of aminolycoside-induced hearing loss Individuals with a MT-RNR1 variant associated with an uncertain risk of aminoglycoside-induced hearing loss m.663A>G
m.669T>C
m.747A>G
m.786G>A
m.807A>G
m.807A>C
m.839A>G
m.896A>G
m.930A>G
m.951G>A
m.960C>del
m.961T>G
m.961T>del
m.961T>del+Cn
m.988G>A
m.1189T>C
m.1243T>C
m.1520T>C
m.1537C>T
m.1556C>T